Skip to content
★ Sign in to follow
ノイ

ノイルイミューン・バイオテック株式会社 Stock: price and insider trades · Japan

JP·Mcap JP¥3.8BHealth Care

ノイルイミューン・バイオテック株式会社: what insiders have been doing

ノイルイミューン・バイオテック株式会社 is a Health Care company. Its directors and officers file their transactions with EDINET (Japan FSA). Over the twelve months to 26 October 2026, 7 filings were filed, from 1 insider.

Only sales appear on the open market, 4 sales in all, filed by 1 insider. No amount is published for 4 filings, which the totals therefore leave out.

With 7 filings in twelve months, the company is more active than the median of 3 filings across the 3,379 companies we follow on the same exchange. The full history, which starts in 2023, counts no purchases against 7 sales.

Typically, a trade is published a median of 7 days after it takes place. That lag is the time during which only the insider knows about the trade. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning.

Elsewhere in the same sector, our signals recently picked up insider purchases at Dynavox Group AB and EssilorLuxottica. This summary is built from EDINET (Japan FSA) disclosures alone and does not predict where the share price will go.

Insider Decl.
21
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
€937,720
7 ops. · all time

Who traded when

BuySale
Okasan Securities Co., Ltd.4 sales

This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.

Fundamental score
Ranked 20,797 of 26,911 companies
32.8
score / 100
Value
10
Quality
56
FCF yld-22%
Earn yld-23%
EV/EBITDA·
ROE-19%
Gross mgn100%
Net mgn·
Debt/EBITDA·
Pillars2/3

Transparent value + quality ranking, distinct from the insider signal.

Financial data

as of FY 2025

FY ended December 2025 · cache

JP¥87
Analyst consensus
1 analysts
1.81/5
JP¥440Target JP¥440(+406%)JP¥440
Income statement
RevenueJP¥5M
Gross profitJP¥5M100% margin
EBITDA-JP¥797.3M-15945% margin
Net income-JP¥793.5M-15870.7% margin
Valuation
P/Book1.1x
Beta0.30
Balance sheet & cash
Market capJP¥3.8B
Total debtJP¥4.9T
Free Cash Flow-JP¥752.2M
Debt / Equity73%
Profitability & ownership
ROE-19.1%
ROA-12.5%
% insiders54.5%
% institutions3.1%
Last declaration on 22 October 2026
Declarations21 total
  • ●
    Related company / holdingExecutives
    0EDINET
    ShareXTKSEDINET:S100Z95G
  • ●
    Related company / holdingExecutives
    0EDINET
    ShareXTKSEDINET:S100Z7P5
  • ▼
    Related company / holdingExecutives
    €96kest.0EDINET
    150,000 sharesShareXTKSEDINET:S100Z7P5:T3
  • ▼
    Related company / holdingExecutives
    €29kest.0EDINET
    50,000 sharesShareXTKSEDINET:S100Z7P5:T4
  • ▼
    Related company / holdingExecutives
    €85kest.0EDINET
    150,000 sharesShareXTKSEDINET:S100Z7P5:T7
  • ▼
    Related company / holdingExecutives
    €115kest.0EDINET
    200,000 sharesShareXTKSEDINET:S100Z7P5:T10
  • ●
    Related company / holdingExecutives
    16EDINET
    100.0% of flowShareXTKSEDINET:S100Z6DJ
  • ●
    Related company / holdingExecutives
    8EDINET
    34.8% of flowShareXTKSEDINET:S100U46F
  • ●
    Related company / holdingExecutives
    8EDINET
    33.9% of flowShareXTKSEDINET:S100U39W
  • ●
    Related company / holdingExecutives
    0EDINET
    ShareXTKSEDINET:S100TMVG
  • ▼
    Related company / holdingExecutives
    98M JPY13EDINET
    400,000 shares@ JP¥244.00100.0% of flowShareXOFFEDINET:S100TMVG:T1
  • ●
    Large shareholderExecutives
    10EDINET
    48.2% of flowShareXTKSEDINET:S100THRM
  • ▼
    Large shareholderExecutives
    €17kest.0EDINET
    20,000 sharesShareXTKSEDINET:S100THRM:T1
  • ▼
    Large shareholderExecutives
    €17kest.0EDINET
    20,000 sharesShareXTKSEDINET:S100THRM:T2
  • ●
    Related company / holdingExecutives
    0EDINET
    ShareXTKSEDINET:S100SZW9
  • ●
    Related company / holdingExecutives
    7EDINET
    15.4% of flowShareXTKSEDINET:S100SV0E
  • ●
    Related company / holdingExecutives
    13EDINET
    100.0% of flowShareXTKSEDINET:S100RC2H
  • ●
    Large shareholderExecutives
    10EDINET
    51.8% of flowShareXTKSEDINET:S100RC1V
  • ●
    Large shareholderExecutives
    13EDINET
    100.0% of flowShareXTKSEDINET:S100RC1P
  • ●
    Related company / holdingExecutives
    7EDINET
    15.8% of flowShareXTKSEDINET:S100R0PC
  • ●
    Related company / holdingExecutives
    13EDINET
    100.0% of flowShareXTKSEDINET:S100R6G9

21 of 21 declarations

About ノイルイミューン・バイオテック株式会社

Noil Immune Biotech Co., Ltd. is a company focused on the health and pharmaceutical sector, specializing in the development of biopharmaceutical solutions. It is listed on the XTKS market.

Recent ranked signals in the same sector

Purchases our model currently ranks for the recommendations list.

All recommendations